+ Tregs impede T cell responses to tumors. They express multiple inhibitory receptors that support their suppressive functions, including T cell Ig and ITIM domain (TIGIT). In melanoma patients, we show that Tregs exhibit increased TIGIT expression and decreased expression of its competing costimulatory receptor CD226 as compared with CD4 + effector T cells, resulting in an increased TIGIT/CD226 ratio. Tregs failed to upregulate CD226 upon T cell activation. TIGIT + Tregs are highly suppressive, stable, and enriched in tumors. TIGIT and CD226 oppose each other to augment or disrupt, respectively, Treg suppression and stability. A high TIGIT/CD226 ratio in Tregs correlates with increased Treg frequencies in tumors and poor clinical outcome upon immune checkpoint blockade. Altogether, our findings show that a high TIGIT/CD226 ratio in Tregs regulates their suppressive function and stability in melanoma. They provide the rationale for novel immunotherapies to activate CD226 in Tregs together with TIGIT blockade to counteract Treg suppression in cancer patients.
Introduction
Tregs, which express the transcription factor Foxp3, regulate innate and adaptive immune cells and maintain self-tolerance (1) . In preclinical cancer models, Tregs potentially abrogate T cell responses to tumors (2) . In humans, Tregs are highly enriched in many solid tumors, including primary melanoma (3, 4) , invaded lymph nodes (5) , and metastatic melanoma (MM) (4) (5) (6) . High-frequency Tregs correlate with tumor progression and poor survival in many solid tumors, including melanoma (7) , and have been associated with poor clinical outcome in melanoma patients (MPs) treated with immunotherapy (8) . Tregs encompass multiple T cell subsets that control immunity through a variety of mechanisms depending on various environmental cues. In particular, Tregs express multiple inhibitory receptors, including CTLA-4, PD-1, Tim-3, and T cell Ig and ITIM domain (TIGIT), which promote their development and suppressive functions (9) (10) (11) (12) (13) . TIGIT is expressed not only by Tregs but also by activated T and NK cells (11, 14) . TIGIT binds with high and low affinity to PVR/CD155 and Nectin-2/CD112, respectively, which are expressed on monocytes, dendritic cells, and tumor cells, including melanoma (15, 16) . Interestingly, TIGIT competes with the costimulatory counter-receptor DNAM-1/CD226 (17) , which binds to the same ligands with lower affinity (11, 18, 19) . Whereas CD226 enhances T cell activation (17, 20) , TIGIT inhibits T cells through T cell-intrinsic inhibitory effects (21) , IL-10 production by dendritic cells upon PVR ligation (11) , or competition with CD226 for PVR binding (22) . In mice and humans, TIGIT is upregulated and coexpressed with PD-1 by CD8 + tumor-infiltrating (Ti) lymphocytes (TILs), and dual PD1/TIGIT blockade enhances potent antitumor CD8 + T cell responses and tumor regression (16, 23) . In contrast to TIGIT, there is ample evidence that CD226 promotes antitumor immune responses mediated by NK and T cells (17, 18, 24, 25) . Several lines of evidence support the role of TIGIT in regulating Treg-mediated suppression in animals and humans. The TIGIT locus is hypomethylated in human Tregs and binds to Foxp3 (26) . In mice and healthy donors (HDs), TIGIT + Tregs represent a subset of activated and highly suppressive Tregs that selectively inhibit Th1 and Th17 responses (12) . Upon activation with an agonistic anti-TIGIT antibody, Tregs displayed increased production of fibrinogen-like protein 2 (FGL2), which promoted TIGIT + Treg-mediated suppression (12) . In mice with B16 melanoma, TIGIT is upregulated by highly suppressive Ti Foxp3 +
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Tregs and acts primarily in Tregs to dampen antitumor immunity (27) . In addition, CD226 + TIGIT -Tregs exhibit reduced demethylation of the Foxp3 gene locus at the Treg-specific demethylated region (TSDR) ex vivo and lower suppressive capacities following in vitro expansion (28 
Foxp3
+ Treg frequencies were higher in MM TILs (mean frequency, 7.4% ± SD 5.9%) than in PBMCs of MPs (1.6% ± 1.2%) and HDs (1.7% ± 0.8%) ( Figure 1A and Supplemental Figure 1A ; supplemental material available online with this article; https://doi. Figure 1E ). Collectively, as compared with Teffs, Tregs in the periphery of HDs and MPs and at tumor sites displayed higher and lower expression of TIGIT and CD226, respectively, resulting in an increased TIGIT/ CD226 ratio that is predominant in the tumor microenvironment.
Tregs fail to upregulate CD226 upon TCR activation. To investigate whether a high TIGIT/CD226 ratio in Tregs is reversed by TCR activation, Tregs were isolated from PBMCs and MM of MPs prior to in vitro stimulation (IVS) and evaluation of CD226 and TIGIT expression by flow cytometry and realtime PCR. In sharp contrast to CD25 -Teffs, circulating and Ti CD25 hi CD127 -Tregs failed to upregulate CD226 upon TCR activation while both Tregs and Teffs upregulated TIGIT (Figure 2, A-C) . Upon TCR activation, circulating Tregs exhibited lower CD226 and higher TIGIT gene expression than Teffs, supporting that CD226 and TIGIT expression in Tregs is regulated at the transcriptional level ( Figure 2D ). To investigate whether TIGIT activation promotes CD226 downregulation, circulating TIGIT + Tregs from MPs were stimulated with anti-CD3/CD28 beads and agonistic anti-TIGIT mAbs (22) prior to CD226 evaluation by flow cytometry. TIGIT activation did not affect CD226 expression, arguing against the role of TIGIT-intrinsic effects in regulating CD226 expression in Tregs ( Figure 2E) .
Collectively, our results show that while both Teffs and Tregs upregulate TIGIT upon TCR activation, Tregs fail to upregulate CD226, resulting in higher TIGIT/CD226 ratio. Figure 4 , A-C). We reasoned that the level of PVR expression on antigen-presenting cells (APCs) may be critical to activate TIGIT and CD226 on Tregs. Indeed, PVR expression on circulating APCs within non-CD3 cells used in these assays (mean percentage ± SD, 35% ± 20% for monocytes and 31% ± 14% for DCs, respectively; Supplemental Figure 4D ) was much lower than on APCs in MM (mean percentage ± SD, 87.2% ± 8.5% for monocytes and 54.4% ± 19% for DCs; Supplemental Figure 5A ), as previously reported (16) . Therefore, we repeated these experiments in the presence of human PVR-Fc with or without anti-TIGIT and/or anti-CD226 mAbs and/or IgG mAbs. We observed that PVR-Fc bound to Fcγ receptors, resulting in increased PVR expression on the surface of APCs (Supplemental Figure 5 Altogether, our findings show that TIGIT and CD226 interact with PVR to exert opposite effects in Tregs, augmenting or counteracting, respectively, Treg-mediated suppression.
PVR impedes Treg stability through CD226 in MPs. We next wanted to investigate whether PVR acts through CD226 to impede Treg stability. We first evaluated the effects of PVR binding to CD226 on Foxp3 expression by Tregs. TIGIT + CD25 hi CD127 -Tregs exhibited decreased Foxp3 expression upon 6-day IVS with anti-CD3/CD28 beads coated with human PVR-Fc (anti-CD3/CD28/PVR beads), but not isotype control mAbs (anti-CD3/CD28/IgG beads), and anti-TIGIT mAbs, as compared with IgG mAbs ( Figure 5A ). We also observed an increased methylation of the TSDR of the Foxp3 locus in TIGIT + CD25 hi CD127 -Tregs upon 6-day IVS with anti-CD3/CD28/PVR beads and anti-TIGIT mAbs as compared with anti-CD3/CD28/IgG beads and IgG mAbs ( Figure 5B ). These effects were abolished when anti-CD226 mAbs were added to the wells ( Figure 5, A and B) . Because Treg instability is associated with the acquisition of effector-like functions, such as the production of proinflammatory cytokines (34, 35), we next investigated the effects of PVR on cytokine production by Tregs. Circulating TIGIT + CD25 hi CD127 -Tregs and Ti CD25 hi CD127 -Tregs produced more IL-2 upon stimulation with anti-CD3/CD28/PVR beads and anti-TIGIT mAbs as compared with anti-CD3/CD28/PVR and/or anti-CD3/CD28/IgG beads and IgG mAbs ( Figure 5C ). These effects, although modest, were abolished by the addition of anti-CD226 mAbs to the wells ( Figure 5C ). In addition, IFN-γ production by Tregs from PBMCs and MM TILs was diminished by CD226 blockade upon stimulation with anti-CD3/CD28/PVR beads (Supplemental Figure 6A) . The production of FGL2 and TGF-β1 by circulating and Ti Tregs did not change significantly upon stimulation with anti-CD3/CD28/PVR beads with or without anti-TIGIT mAbs with or without anti-CD226 mAbs (Supplemental Figure 6B) .
Altogether, our findings show that PVR acts directly on CD226 in Tregs to decrease Foxp3 expression and promote the acquisition of effector-like functions, disrupting Treg stability.
A high TIGIT/CD226 ratio in Tregs in MM correlates with high-Treg frequencies and poor clinical outcome upon ICB.
To investigate the in vivo relevance of our findings in vitro, we next assessed whether a high TIGIT/ Error bars indicate SEM. P values were obtained by repeated-measures ANOVA followed by Tukey's test. *P < 0.05; **P < 0.01; ***P < 0.001. ratio in Ti Tregs, but not circulating Tregs, was significantly lower in responders (mean ± SD, MFI TIG-IT/CD226 ratio, 3.8 ± 2.1) than in nonresponders (10.1 ± 6.8) ( Figure 6B ). The median progression-free survival (PFS) was 12 months for MPs with a TIGIT/CD226 ratio of Ti Tregs < 5.6 (i.e., median of the MFI TIGIT/CD226 ratio in Ti Tregs) and 2 months for MPs with a ratio > 5.6 ( Figure 6C , P = 0.039).
Altogether, our findings show that, in melanoma, a high TIGIT/CD226 ratio in Tregs correlates with high Treg frequencies in tumors and poor clinical outcome upon ICB.
Discussion
In the present study, we show that Tregs in the periphery and tumors of MPs exhibit a high TIGIT/CD226 expression ratio that regulates their functions and stability. Consistent with previous studies in HDs and mice with melanoma tumors (12, 27) , we observed that Tregs express high-level TIGIT, with higher expression at tumor sites than in the periphery. As compared with TIGIT -Tregs, TIGIT + Tregs exhibited higher suppressive capacities, were more mature/activated, and expressed higher levels of molecules involved in Treg homeostasis, suppressive functions, and stability, including CTLA-4 (13), CD39 (29) , PD1 (9), Tim-3 (10 ), Nrp1 (30) , and Helios (33, 34) . They also exhibited higher demethylation of the Foxp3 TSDR, a hallmark of stable and natural Tregs (39) (40) (41) . In sharp contrast to Teffs, circulating Tregs in HDs and MPs and Ti Tregs displayed lower expression of CD226, which competes with TIGIT for binding to the same ligands, while Ti Tregs further downregulated CD226 as compared with circulating Tregs. Hence and as compared with Teffs, Tregs exhibited an increased TIGIT/CD226 ratio that is higher in tumors than in PBMCs. Strikingly and unlike Teffs, Tregs in PBMCs and tumors of MPs failed to upregulate CD226 expression upon TCR activation, while they upregulated TIGIT, further increasing the TIGIT/CD226 expression ratio. This observation contrasts with the imbalance of TIGIT/ CD226 expression of CD8 + TILs observed in MM but not in the periphery (16) . This striking difference indicates that different mechanisms regulate CD226 expression in Tregs and Teffs. Along these lines, we observed that CD226 expression was decreased at the transcriptional level in Tregs upon TCR activation but not in Teffs, supporting that CD226 gene expression is repressed in activated Tregs in the periphery and at tumor sites. hi CD127 -Tregs isolated from metastatic melanoma (MM) tumor-infiltrating lymphocytes (TILs) stimulated as in A (n = 16). Results represent the mean of independent experiments. Error bars indicate SEM. P values were obtained by repeated-measures ANOVA followed by Tukey's test. *P < 0.05; **P < 0.01; ***P < 0.001.
In Tregs, PVR acted on TIGIT and CD226 to augment or counteract Treg-mediated suppression, respectively. The CD226-mediated immunostimulatory effects of PVR were observed in the presence of Tregs isolated either from the periphery or tumor sites and required high-level PVR (i.e., PVR-Fcloaded APCs). In contrast, the TIGIT-mediated immunosuppressive effects of PVR were observed only in the presence of Ti Tregs, and PVR-Fc-loaded APCs, suggesting that they required both high TIGIT and high PVR levels. It is therefore expected that the high TIGIT/CD226 ratio in Ti Tregs cooperates with high-level PVR expressed by tumor cells and APCs in the tumor microenvironment to enhance Treg-suppressive functions. In HDs, FGL2 appears to mediate TIGIT + Treg-mediated suppression (12) . In line with this study, our findings show that TIGIT + Tregs in MPs produced higher FGL2 levels than TIGIT -Tregs upon TCR activation. However, upon CD226 stimulation with PVR (i.e., PVR-Fc plus anti-TIGIT mAbs), Tregs exhibited less suppression but not lower FGL2 production, suggesting that FGL2 is not directly involved in CD226-mediated regulation of Treg functions.
PVR-mediated CD226 activation together with TIGIT blockade decreased Foxp3 expression while increasing Foxp3 TSDR methylation in Tregs of MPs and modestly enhanced their capacity to produce the proinflammatory cytokine IL-2. These findings support the role of PVR in disrupting Treg stability through CD226 by affecting three main features that define Treg stability, including potent suppressive activity, sustained Foxp3 expression, and lack of effector activity (42) . In strong support of the CD226-mediated effects of PVR on Treg stability in vivo, we observed a positive correlation between the frequencies of CD25 hi
Foxp3
+ Tregs in MM and the TIGIT/CD226 ratio in Ti Tregs. Such a correlation was not observed in the periphery where PVR levels and TIGIT/CD226 ratio in Tregs are less pronounced. A high TIGIT/ CD226 ratio in Ti Tregs was associated with poor clinical outcome and decreased PFS in MPs treated with ICB, suggesting that the TIGIT/CD226 ratio in Tregs is a marker of Treg stability
In summary, our findings show that Tregs express high-level TIGIT and low-level CD226 as compared with Teffs, resulting in a high ratio of TIGIT/CD226 expression, which is further increased at tumor sites. In sharp contrast to TIGIT, which promotes Ti Treg-mediated suppression, CD226 disrupts Treg-mediated suppression and stability in the periphery and at tumor sites, upon PVR binding. TIGIT-PerCPeFluor710 (clone MBSA43) and CD11c-Alexa700 (clone 3.9) (Thermo Fisher Scientific); PD-1-PECy7 (clone EH12.2H7) or Nrp1-PECy7 (clone 12C2) (BioLegend); and CD25-APCCy7 (clone M-A251, BD Biosciences). Viability of cells was assessed using the LIVE/DEAD Violet Viability/Vitality Kit (Thermo Fisher Scientific). In some experiments, CD4 + T cells were permeabilized after fixation and intracellularly stained with Helios-Pacific Blue (clone 22F6, Biolegend) and/or Foxp3-PE (clone PCH101, Thermo Fisher Scientific) or Foxp3-FITC (clone PCH101) using Foxp3 Staining Buffer Set (Thermo Fisher Scientific). In some experiments, CD4 + T cells were stimulated for 6 days with either with allogeneic non-CD3 cells and 1 μg/ml anti-CD3 mAbs (clone OKT3, Thermo Fisher Scientific) or with anti-CD3/CD28-coated MACSiBeads (Miltenyi Biotec) in the presence of agonistic anti-TIGIT mAbs (clone 328.28.2.1; provided by BMS) or IgG control mAbs (BMS), plate-bound at 50 mg/ml, or with Dynabeads M-450 Tosylactivated beads (Thermo Fisher Scientific) coated with anti-CD3 (10%) and anti-CD28 (10%) mAbs and either human PVR-Fc construct (provided by BMS) or IgG control Abs (80%), in the presence of blocking anti-TIGIT (clone 10D7.G8; provided by BMS) and/or anti-CD226 (Abcam; clone DX11) mAbs and/or IgG isotype control mAbs, before phenotypic analysis. Samples were acquired on a FACS LSRII machine (BD Biosciences) and analyzed using Flowjo software v10 (Tree Star). For sorting of CD4 + T cell subsets, cells were stained with CD4-BV510, CD127-FITC, and CD25-APCCy7 with or without TIGIT-PerCPeFluor710 and sorted under sterile conditions on a FACSAria machine (BD Biosciences).
CFSE-based proliferation assays. In inhibition of proliferation assays, naive (CD45RA + ) CD8 + T cells were purified from PBMCs of HDs by magnetic cell separation and stained with CFSE (Thermo Fisher Scientific). CFSE-labeled naive T cells were cultured for 6 days with autologous non-CD3 cells in the presence or absence of different numbers of CD4 + T cells isolated by FACS from PBMCs or TILs of MPs and with 1 μg/ml anti-CD3 mAbs (clone OKT3) and IL-2 (50 IU/ml; Peprotech). In some experiments, cells were stimulated in the presence of 10 μg/ml fully human anti-TIGIT blocking mAbs (clone 10D7.G8) and/or blocking anti-CD226 mAbs (clone DX11) and/or IgG isotype control mAbs, with or without 10 μg/ml human PVR-Fc construct. After stimulation, cells were stained with CD4-BUV395-(clone RPA-T4, BD Biosciences) as well as CD226-PE-, CD14-ECD-and CD19-ECD-, TIGIT-PerCPeFluor710-, and CD8-APCCy7-conjugated (SK1) (BD Biosciences) mAbs. Viability of cells was assessed during flow cytometric analysis using the LIVE/DEAD Violet Viability/Vitality Kit (Thermo Fisher Scientific).
Multiplex cytokine and ELISA assays. 5 × 10 4 FACS-sorted CD4 + T cells were incubated for 6 days in 96-well plates containing 200 μl culture medium with same number of anti-CD3/CD28 MACSiBeads. In some experiments, CD4 + T cells were incubated with same number of Dynabeads M-450 Tosylactivated beads coated with anti-CD3 (10%) and anti-CD28 (10%) mAbs and either human PVR-Fc construct or IgG control Abs (80%) in the presence of blocking anti-TIGIT (10D7.G8) and/or anti-CD226 (DX11) mAbs and/or IgG isotype control mAbs. Cytokine production in culture supernatants was determined using the Human TH17 Magnetic Bead Panel (HT17MG-14K-10; EMD Millipore) and TGF-β 1, 2, 3 Magnetic Bead Panel (TGFBMAG-64K-03; EMD Millipore) according to manufacturers' instructions. FGL2 production in culture supernatants was assessed by ELISA using the LEGEND MAX Human FGL2 ELISA Kit (Biolegend) according to the manufacturer's instructions.
Quantitative PCR. 5 × 10 5 FACS-sorted CD4 + T cells were stimulated for 6 days with an equal number of anti-CD3/CD28-coated MACSiBeads. RNA was extracted with RNeasy Mini Kits (Qiagen), and cDNA was prepared by reverse transcription using M-MLV Reverse Transcriptase (Thermo Fisher Scientific). RT-PCR was performed with StepOne System (Thermo Fisher Scientific). All samples were normalized to the expression of β-glucuronidase (β-Gus). TIGIT expression was detected using previously described primers and probes (11) . CD226 expression was detected using the following forward (F) and reverse (R) primers and probe (P): F (5′-CAGCACTCACATCTCAAGAACC-3′), R (5′-TGTTCTCGGCAAAGG-GAACT-3′), and P (5′-FAM-ACAGAGCTCTATGTGAAGAGGTGCTTTGGC-3′BHQ).
Foxp3 TSDR methylation analysis. FACS-sorted CD4 + T cells were either analyzed ex vivo or after IVS with equal number of anti-CD3/CD28 Dynabeads coated with either human PVR-Fc construct or IgG control Abs in the presence of anti-TIGIT (clone 10D7.G8) and/or anti-CD226 (clone DX11) mAbs and/ or IgG isotype control mAbs. Methylation analysis of the TSDR region within the first intron of the Foxp3 gene locus was performed on genomic DNA extracted from CD4 + T cells as previously described (43) . Statistics. The normality of each variable was evaluated using the Shapiro-Wilk test. Statistical comparison between two groups was assessed by 2-tailed paired or unpaired t tests. For multiple group comparison, in cases of normally distributed data, statistical significance was assessed by a 1-way or repeated-measures ANOVA for independent and dependent data, respectively, followed by Tukey's multiple comparisons test. In cases of not normally distributed data, the comparison of variables was performed with a Kruskal-Wallis test or a Friedman test for unpaired and paired data, respectively, followed by a Dunn's multiple comparisons test. For correlation studies, P values were obtained by Pearson tests. PFS was estimated by Kaplan-Meier method and compared using the log-rank test. P values of less than 0.05 were considered significant. Statistical analysis was performed using GraphPad Prism 5.
Study approval. All studies using human tissues and primary human cells were approved by the IRB of UPCI. Written informed consent was received from patients prior to their inclusion in the study.
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